ICMR spent Rs 35 crore on the research and development of the indigenous vaccine that is being manufactured by Bharat Biotech, an has made a profit of Rs 136 crore on the vaccine. The total budget for the development of health research, of which ICMR is a part, for FY 2022-23 is Rs 3,200 crore.

ICMR and Bharat Biotech developed Covaxin together, and MoS Health Bharati Pawar says in written reply that the research body spent Rs 35 crore on its development.

The Indian Council of Medical Research (ICMR) has received a royalty of Rs 171.74 crore from Bharat Biotech on the sale of Covaxin till 31 January 2022, the government told Parliament Tuesday.

“ICMR has received royalty of Rs 171.74 crore till 31 January 2022 from Bharat Biotech from sales of Covaxin. ICMR has spent around Rs 35 crore in R&D of Covaxin. Funds with ICMR are utilised for health research activities including emerging research priorities and research capacity building,” Minister of State for Health Bharati Pravin Pawar said in a written reply to a question from Congress’ Mallikarjun Kharge, Leader of Opposition in the Rajya Sabha.

Covaxin was developed as a joint venture between the ICMR and Bharat Biotech. The SARS-CoV-2 virus (original Wuhan strain) was isolated by the National Institute of Virology in Pune in January 2020. It was shared with the manufacturer and a whole virion inactivated vaccine was developed, using the technology used for some of the earliest vaccines known to humankind, such as the polio vaccine.

Read more- https://theprint.in/india/icmr-received-rs-171-74-cr-in-royalty-from-sale-of-covaxin-till-31-jan-govt-tells-rajya-sabha/824536/?amp